NOCDURNA
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2023 | $210,090 | 10,333 | 6,082 |
| 2022 | $488,406 | 23,129 | 8,588 |
| 2021 | $214,014 | 597 | 335 |
| 2020 | $880,205 | 370 | 80 |
| 2019 | $2.9M | 3,876 | 1,623 |
| 2018 | $1.4M | 1,178 | 783 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $4.6M | 712 | 76.3% |
| Food and Beverage | $717,379 | 38,220 | 11.8% |
| Honoraria | $249,530 | 134 | 4.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $228,318 | 78 | 3.8% |
| Consulting Fee | $174,931 | 28 | 2.9% |
| Travel and Lodging | $63,961 | 306 | 1.1% |
| Education | $1,314 | 5 | 0.0% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Randomised, Double-blind, Placebo-controlled, Response-adaptive Dose-finding Trial Investigating the Efficacy, Safety and Tolerability of Oral Doses of FE 201836, With Desmopressin Orally Disintegrating Tablet as a Benchmark, During 12 Weeks of Treatment for Nocturia Due to Nocturnal Polyuria in Adults | Ferring Pharmaceuticals AS | $2.5M | 0 |
| A Randomised, Double-blind, Placebo-controlled, Response-adaptive Dose-finding Trial Investigating the Efficacy, Safety and Tolerability of Oral Doses of FE 201836, With Desmopressin Orally Disintegrating Tablet as a Benchmark, During 12 Weeks of Treatment for Nocturia Due to Nocturnal Polyuria in Adults | Ferring International Pharmascience Center US | $2.1M | 0 |
Top Doctors Receiving Payments for NOCDURNA — Page 3
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Urology | Dallas, TX | $1,963 | 2 |
| , MD | Urogynecology and Reconstructive Pelvic Surgery | Tucson, AZ | $1,950 | 1 |
| , M.D | Internal Medicine | Auburn Hills, MI | $1,154 | 14 |
| , MD | Internal Medicine | Coral Gables, FL | $1,032 | 13 |
| , M.D | Urology | Las Vegas, NV | $1,023 | 36 |
| , MD | Urology | Commerce Township, MI | $871.54 | 62 |
| , M.D | Urogynecology and Reconstructive Pelvic Surgery | Lake Barrington, IL | $772.18 | 4 |
| , P.A | Urology | Clifton, NJ | $756.56 | 24 |
| , MSN, RN, APN, ANP-BC | Adult Health | Somerville, NJ | $736.76 | 25 |
| , MD | Urology | Mountain View, CA | $723.77 | 30 |
| , MD | Urology | Coral Springs, FL | $700.58 | 20 |
| , FNP | Nurse Practitioner | Helotes, TX | $673.18 | 18 |
| , M.D | Internal Medicine | High Point, NC | $653.81 | 11 |
| , MD | Internal Medicine | Melrose Park, IL | $650.93 | 21 |
| , MD | Urology | St Louis, MO | $624.31 | 40 |
| , M.D | Family Medicine | Vancouver, WA | $615.56 | 39 |
| , MD | Endocrinology, Diabetes & Metabolism | Denver, CO | $608.99 | 55 |
| , D.O | Family Medicine | Rancho Cucamonga, CA | $608.91 | 20 |
| , M.D | Internal Medicine | Oak Park, IL | $602.05 | 28 |
| , MD | Surgery | Vancouver, WA | $589.73 | 36 |
| , MD | Urology | Greenwood, IN | $588.10 | 25 |
| Tiffany Cheng | Physician Assistant | Newport Beach, CA | $582.99 | 57 |
| , M.D | Student in an Organized Health Care Education/Training Program | Akron, OH | $582.56 | 18 |
| , MD | Endocrinology, Diabetes & Metabolism | Newport Beach, CA | $580.49 | 60 |
| , M.D | Specialist | Westfield, NJ | $572.99 | 49 |
Manufacturing Companies
- Ferring Pharmaceuticals AS $2.5M
- Ferring International Pharmascience Center US $2.1M
- Antares Pharma, Inc. $890,146
- Ferring Pharmaceuticals Inc. $521,739
- Ferring International Center SA $96.38
Product Information
- Type Drug
- Total Payments $6.1M
- Total Doctors 12,343
- Transactions 39,483
About NOCDURNA
NOCDURNA is a drug associated with $6.1M in payments to 12,343 healthcare providers, recorded across 39,483 transactions in the CMS Open Payments database. The primary manufacturer is Ferring Pharmaceuticals AS.
Payment data is available from 2018 to 2023. In 2023, $210,090 was paid across 10,333 transactions to 6,082 doctors.
The most common payment nature for NOCDURNA is "Unspecified" ($4.6M, 76.3% of total).
NOCDURNA is associated with 2 research studies, including "A Randomised, Double-blind, Placebo-controlled, Response-adaptive Dose-finding Trial Investigating the Efficacy, Safety and Tolerability of Oral Doses of FE 201836, With Desmopressin Orally Disintegrating Tablet as a Benchmark, During 12 Weeks of Treatment for Nocturia Due to Nocturnal Polyuria in Adults" ($2.5M).